RenovoRx, Inc. (RNXT)
1.20
+0.04
(+3.45%)
USD |
NASDAQ |
Oct 20, 16:00
1.215
+0.02
(+1.25%)
After-Hours: 20:00
RenovoRx Research and Development Expense (TTM) : 5.614M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 5.614M |
| March 31, 2026 | 5.84M |
| December 31, 2025 | 6.254M |
| September 30, 2025 | 6.329M |
| June 30, 2025 | 6.294M |
| March 31, 2025 | 6.41M |
| December 31, 2024 | 6.025M |
| September 30, 2024 | 5.224M |
| June 30, 2024 | 5.203M |
| March 31, 2024 | 5.586M |
| December 31, 2023 | 5.667M |
| Date | Value |
|---|---|
| September 30, 2023 | 5.668M |
| June 30, 2023 | 4.885M |
| March 31, 2023 | 4.35M |
| December 31, 2022 | 4.301M |
| September 30, 2022 | 4.626M |
| June 30, 2022 | 4.547M |
| March 31, 2022 | 3.693M |
| December 31, 2021 | 3.039M |
| September 30, 2021 | 2.665M |
| June 30, 2021 | 2.30M |
| March 31, 2021 | 2.569M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Enanta Pharmaceuticals, Inc. | 86.24M |
| Travere Therapeutics, Inc. | 227.14M |
| REGENXBIO, Inc. | 213.77M |
| Krystal Biotech, Inc. | 53.39M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |